CJC-1295 & Ipamorelin
CJC-1295 and ipamorelin are peptides discussed in the context of growth-hormone (GH) axis signalling. They are often described as acting through complementary pathways—CJC-1295 via GHRH-related signalling and ipamorelin via ghrelin (GHSR) signalling— with the goal of influencing pulsatile GH release. Evidence quality, clinical frameworks, and regulatory status vary by jurisdiction. Any peptide-related therapy must be clinician-guided and individualised.
What are CJC-1295 & ipamorelin?
CJC-1295 is commonly described as a growth hormone–releasing hormone (GHRH) analogue designed to stimulate GH release via the pituitary. Some formulations are discussed as having an extended half-life (depending on the specific version and chemistry), which may influence dosing strategy and monitoring needs.
Ipamorelin is frequently described as a growth hormone secretagogue that acts through the ghrelin receptor (GHSR). In research and clinical discussions, the combination is often positioned to support GH pulse signalling via two distinct receptor pathways.
This information is general and educational. It is not medical advice and is not a substitute for care from a qualified clinician. Any peptide-related therapy must be clinician-guided and individualised.
How they work
The GH axis is regulated by multiple signals, including GHRH, somatostatin, and ghrelin. CJC-1295 is generally discussed as engaging GHRH-related signalling to encourage GH release, while ipamorelin engages ghrelin-receptor signalling (GHSR) to support GH pulse activity. Downstream, GH signalling can influence IGF-1 production, recovery physiology, and body composition pathways.
In practice, clinicians focus on measurable outcomes and safety: symptom patterns, sleep and recovery markers, body composition goals, and objective monitoring (including relevant labs) where indicated.
Key benefits and areas of clinical interest
CJC-1295 and ipamorelin are most commonly discussed in relation to recovery, sleep-adjacent physiology, and body composition goals. The themes below reflect areas of investigation and clinical discussion, not guaranteed outcomes.
GH secretion is naturally pulsatile and influenced by sleep architecture. Some protocols are discussed in relation to sleep-adjacent recovery planning, though individual results vary and require monitoring.
GH/IGF-1 pathways are discussed in research relating to lean mass preservation and fat-loss support when paired with training and nutrition strategy.
In performance settings, clinicians typically evaluate overall recovery capacity (sleep, nutrition, stress, load management) rather than relying on a single intervention.
Some discussions include metabolic markers and inflammatory-adjacent indicators, depending on the patient’s baseline profile and goals.
Mechanisms and pathways (high-level)
These peptides are discussed primarily through the GH/IGF-1 axis. High-level mechanisms commonly referenced include:
- GHRH receptor signalling (CJC-1295): supports GH release via pituitary stimulation.
- Ghrelin receptor (GHSR) signalling (ipamorelin): supports GH pulse activity via secretagogue pathways.
- Downstream IGF-1 pathways: GH signalling can influence IGF-1 production and related physiology.
- Recovery and tissue turnover signalling: discussed in relation to sleep, training adaptation, and repair physiology.
How clinicians assess suitability
Suitability is assessed case-by-case. Clinicians consider goals (sleep/recovery support, body composition), medical history, medications, baseline lab markers, and overall endocrine context before considering any GH-axis–related approach.
- Baseline symptoms, sleep patterns, and recovery capacity
- Body composition goals and training load
- Contraindications, medication interactions, and medical history
- Monitoring plan (including relevant labs where indicated)
Safety and considerations
GH-axis therapies require careful clinical oversight. Potential issues discussed in clinical contexts can include fluid retention, changes in appetite, altered glucose dynamics, and other endocrine-adjacent effects depending on dosing and individual sensitivity. Product quality, dosing, and monitoring must be managed by a qualified clinician.
If you have a medical condition, are pregnant or breastfeeding, have a history of cancer, or take prescription medications, seek clinician advice before commencing any therapy. Seek urgent medical care for severe or concerning symptoms.
Access pathway
At Revivo, peptide-related therapies are considered only after a clinician-guided assessment. If suitable, your clinician will outline the rationale, expected monitoring, and any required testing to support safe decision-making within a structured care plan.
FAQs
Why are CJC-1295 and ipamorelin often paired together?
They are discussed as complementary because CJC-1295 targets GHRH-related signalling while ipamorelin targets ghrelin-receptor (GHSR) signalling, which may support GH pulse activity through two pathways. Clinical relevance and outcomes vary by individual.
Is this the same as taking growth hormone?
No. These peptides are generally described as influencing the body’s own GH signalling pathways rather than supplying exogenous growth hormone. A clinician can explain whether any approach is appropriate for your goals and risk profile.
What is typically monitored if someone is using GH-axis peptides?
Monitoring may include symptoms, sleep and recovery markers, body composition trajectory, and relevant labs where indicated (often including endocrine and metabolic markers). The exact monitoring plan is individualised.
Is CJC-1295 the same thing as “MOD GRF (1-29)”?
Not always. Naming is often used inconsistently. Different GHRH-analogue peptides and formulations are discussed under similar labels, and half-life characteristics can differ. Clinicians should clarify exactly which compound and formulation is being considered.